[Federal Register Volume 68, Number 36 (Monday, February 24, 2003)]
[Notices]
[Page 8613]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 03-4218]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel, Collaborative Clinical Studies in Drug Abuse.
    Date: March 6, 2003.
    Time: 11:30 a.m. to 2 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852.
    Contact Person: Mark R. Green, Ph.D., Chief, CEASRB, Office of 
Extramural Affairs, National Institutes on Drug Abuse, National 
Institute of Health, DHHS, Room 3158, MSC 9547, 6001 Executive 
Boulevard, Bethesda, MD 20892-9547, (301) 435-1431.
    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug 
Abuse Scientist Development Award for Clinicians, Scientist 
Development Awards, and Research Scientist Awards; 93.278, Drug 
Abuse National Research Service Awards for Research Training; 
93.279, Drug Abuse Research Programs, National Institutes of Health, 
HHS)

    Dated: February 13, 2003
LaVerne Y. Stringfield,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 03-4218 Filed 2-21-03; 8:45 am]
BILLING CODE 4140-01-M